Pixelgen Technologies, a Stockholm startup mapping the architecture of cell-surface proteins, has raised €13.26M in a round led by new investor Flat Capital, with existing backers Industrifonden and Navigare Ventures returning.
Flat Capital CEO Rickard El Tarzi will join Pixelgen’s board as part of the deal.
Four founders, Fredrik Fredriksson, Alvaro Martinez Barrio, Fredrik Dahl and Filip Karlsson, set up Pixelgen in 2020 and came out of stealth in December 2022 after a €5.13M raise. Its pitch to researchers: stop counting how much protein is present and start seeing how it is arranged, clustered and placed on each cell’s surface.
The Proxiome Kit, powered by what the company calls the Proximity Network Assay, is billed as the first platform to enable high-throughput mapping of molecular cell architecture at nanoscale resolution. That matters because the spatial arrangement of proteins drives much of how cells behave, in ways abundance measurements alone cannot capture.
Applications span immunology, hematology, oncology and cell therapy, where understanding cell-surface architecture can inform how disease progresses or how a treatment response unfolds.
Pixelgen says the financing gives it resources to expand globally as demand grows for its kit and its data analysis and visualization software, positioning the startup to sell biology tools to labs chasing deeper views of cell state.
